SM-25-RE

Key Features

• 1
  1.Effective in Slowing CKD Progression"SM-25-RE contains ACE inhibitors and SGLT2 inhibitors, which have been proven to reduce the risk of kidney failure by 39% and 30%, respectively, and slow CKD progression significantly."
• 2
  2.Reduces Cardiovascular Risk"This medication includes blood pressure-lowering therapies, which have been shown to reduce major cardiovascular events by 18% and 24%, respectively, and all-cause mortality by 28%."
• 3
  3.Personalized Treatment Approach"SM-25-RE is prescribed based on individual clinical factors, including albuminuria levels, underlying causes, and comorbidities, ensuring a personalized treatment plan for each patient."
• 4
  4.Comprehensive Management"The medication addresses multiple aspects of CKD management, including reducing albuminuria levels, treating hypertension, and lowering lipid levels, making it a comprehensive solution for patients."